We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tools
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Greencare Capital plc | AQSE:GRE | Aquis Stock Exchange | Ordinary Share | GB00BJBYK814 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|
| 0.00 | 0.0% | 0.00 | - |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | 0 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 31/7/2023 | 13:08 | ALNC |  EARNINGS SUMMARY: National World profit down; AFC Energy revenue down |
| 31/7/2023 | 06:00 | UKREG | MaxRets Ventures PLC 2023 Interim Results |
| 22/6/2023 | 16:00 | UKREG | MaxRets Ventures PLC Result of AGM |
| 30/5/2023 | 06:00 | UKREG | MaxRets Ventures PLC Notice of AGM |
| 27/4/2023 | 13:44 | ALNC | EARNINGS SUMMARY: Synairgen loss narrows; aims to develop SNG001 |
| 27/4/2023 | 06:00 | UKREG | MaxRets Ventures PLC 2022 Final Results |
| 07/2/2023 | 14:31 | ALNC | IN BRIEF: MaxRets officially changes name from Greencare Capital |
| 07/2/2023 | 07:00 | UKREG | MaxRets Ventures PLC Change of Name to MaxRets Ventures plc |
| 28/12/2022 | 13:23 | ALNC | IN BRIEF: Greencare Capital to change name to MaxRS Ventures |
| 28/12/2022 | 12:00 | UKREG | Greencare Capital PLC Result of General Meeting |
Greencare Capital (GRE) Share Charts1 Year Greencare Capital Chart |
|
1 Month Greencare Capital Chart |
Intraday Greencare Capital Chart |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 11/10/2002 08:32 by izziebon basic info on greenchip; looks good business idea, at least!Greenchip Greenchip's current business model involves seeking to secure an option, from owners of intellectual property, over newly developed products, ideas and technologies ('Products') in respect of the exclusive European rights to exploit and commercialise those Products. The companies targeted by Greenchip are typically already established in the USA, Canada, Australia, Asia and the Pacific region and own the rights to the Products. Options typically have a three-month duration and Greenchip does not intend to pay for the option. The intention is to convert the option agreement into an exclusive license agreement. Greenchip's principal source of license opportunities is through a referral agreement with Oceanic Management, a North American-based investment and technology ventures company, through which license opportunities are received. Greenchip focuses on Products that have undergone development and are being, or are about to be, commercially exploited. Greenchip seeks to avoid partnering with start up companies and preferably targets companies already quoted on an overseas stock exchange. Typically the owner of the Products will grant an exclusive license to a company ('the Licensee Company'), which initially is owned equally by Greenchip and the licensor. Subsequently, as the European business is developed and finance is raised the shareholdings of the two parties will usually be diluted. It is intended that, where appropriate, shareholders in Greenchip will have an opportunity to apply for any IPO offering for each Licensee Company. Greenchip's plan is, in due course, to realise all or part of its shareholding in each Licensee Company. Currently, Greenchip has established a portfolio of Licensee companies with which it is working and in which it has invested to exploit the Products, including the following: Environmental Technology Division Genesis Microbial Limited. It is intended that Genesis Microbial Limited will have exclusive rights to exploit within Europe two bio-microbial products the first of which digests fat and grease and is used primarily in the catering trade to keep drains clear. The second product is anticipated to be used mainly in pest control to prevent insect larvae from developing. Life Science & Medicine Division Perioplus Europe Limited. It is intended that Perioplus Europe Limited will have exclusive rights to exploit within Europe an anti-bacterial chlorhexidine mouthwash. The mouthwash, which does not have harmful additivies, is currently in advanced laboratory testing with a major pharmaceutical and consumer healthcare multinational. Infantcare (UK) Limited. Infantcare has exclusive European rights to develop and exploit a patented and professionally endorsed electrically operated crib called 'The Babysleeper' which oscillates and calms babies, thus promoting sleep. Internet Division Ecomextra plc. Ecomextra plc is an OFEX quoted provider of packaged e-commerce solutions to SME's. Word of Mail Limited - It is intended that Word of Mail Limited will hold a license under which it may exploit a permission based multi-level viral marketing software package within the UK. Whats-online Limited - It is intended that Whats-online Limited will have a license to exploit a web based aggregate affiliate marketing program within the European Union. Biztalk Limited - Biztalk is a business information portal for SME's. This US website currently has over 100,000 registered members. It is intended that Biztalk Limited will have an exclusive license to develop and exploit a similar website in the European Union. Global Leading Edge Technologies Europe Limited ('GLETE')- It is intended that GLETE will have exclusive rights to develop and exploit, within Europe, a fax product that incorporates technology from Hewlett Packard, Symantec and 3Com that enables organisations to send long distance faxes via the internet and benefit from the reduced telecommunications rates available using this medium. In addition, Greenchip holds 19.1 % of the issued share capital of Great Panther Inc. This company intends to secure license rights to technologies for exploitation in Asia Pacific. |
Posted at 09/1/2002 16:08 by donnydave Its got me stumped why on earth would anyone want to sell @ 1p when the bid price is 2.5p. I can only assume that it has something to do with the cancelation of the old shares and then the issueing of the enlarged share capital. |
Posted at 09/1/2002 08:51 by rangers99 Just to change the subject completely and apologies if this is the wrong place but why the big drop in GRE's price today. Anyone have any ideas? |
Posted at 07/11/2000 14:53 by kevin prescott Here's the only stuff I could find:Greenchip Investments PLC 30 October 2000 GREENCHIP INVESTMENTS PLC Greenchip Investments Plc ("Greenchip" or "the Company") announces that its shares commenced trading today on the Alternative Investment Market ("AIM"). Introduction and History The Company was incorporated in June 1996, to acquire Infantcare (UK) Limited which remains a wholly owned subsidiary. Following this acquisition the Ordinary Shares commenced trading on OFEX in November 1996. The Company's existing primary business has involved securing rights to exploit, normally within Europe, technologies which, typically, have been developed by corporations based in North America and/or Asia Pacific. The Company has had a particular focus on life science, environmental technology and internet related technologies. Greenchip Greenchip's current business model involves seeking to secure an option, from owners of intellectual property, over newly developed products, ideas and technologies ("Products") in respect of the exclusive European rights to exploit and commercialise those Products. The companies targeted by Greenchip are typically already established in the USA, Canada, Australia, Asia and the Pacific region and own the rights to the Products. Options typically have a three-month duration and Greenchip does not intend to pay for the option. The intention is to convert the option agreement into an exclusive license agreement. Greenchip's principal source of license opportunities is through a referral agreement with Oceanic Management, a North American-based investment and technology ventures company, through which license opportunities are received. Greenchip focuses on Products that have undergone development and are being, or are about to be, commercially exploited. Greenchip seeks to avoid partnering with start up companies and preferably targets companies already quoted on an overseas stock exchange. Typically the owner of the Products will grant an exclusive license to a company ("the Licensee Company"), which initially is owned equally by Greenchip and the licensor. Subsequently, as the European business is developed and finance is raised the shareholdings of the two parties will usually be diluted. It is intended that, where appropriate, shareholders in Greenchip will have an opportunity to apply for any IPO offering for each Licensee Company. Greenchip's plan is, in due course, to realise all or part of its shareholding in each Licensee Company. Currently, Greenchip has established a portfolio of Licensee companies with which it is working and in which it has invested to exploit the Products, including the following: Environmental Technology Division Genesis Microbial Limited. It is intended that Genesis Microbial Limited will have exclusive rights to exploit within Europe two bio-microbial products the first of which digests fat and grease and is used primarily in the catering trade to keep drains clear. The second product is anticipated to be used mainly in pest control to prevent insect larvae from developing. Life Science & Medicine Division Perioplus Europe Limited. It is intended that Perioplus Europe Limited will have exclusive rights to exploit within Europe an anti-bacterial chlorhexidine mouthwash. The mouthwash, which does not have harmful additivies, is currently in advanced laboratory testing with a major pharmaceutical and consumer healthcare multinational. Infantcare (UK) Limited. Infantcare has exclusive European rights to develop and exploit a patented and professionally endorsed electrically operated crib called "The Babysleeper" which oscillates and calms babies, thus promoting sleep. Internet Division Ecomextra plc. Ecomextra plc is an OFEX quoted provider of packaged e-commerce solutions to SME's. Word of Mail Limited - It is intended that Word of Mail Limited will hold a license under which it may exploit a permission based multi-level viral marketing software package within the UK. Whats-online Limited - It is intended that Whats-online Limited will have a license to exploit a web based aggregate affiliate marketing program within the European Union. Biztalk Limited - Biztalk is a business information portal for SME's. This US website currently has over 100,000 registered members. It is intended that Biztalk Limited will have an exclusive license to develop and exploit a similar website in the European Union. Global Leading Edge Technologies Europe Limited ("GLETE")- It is intended that GLETE will have exclusive rights to develop and exploit, within Europe, a fax product that incorporates technology from Hewlett Packard, Symantec and 3Com that enables organisations to send long distance faxes via the internet and benefit from the reduced telecommunications rates available using this medium. In addition, Greenchip holds 19.1 % of the issued share capital of Great Panther Inc. This company intends to secure license rights to technologies for exploitation in Asia Pacific. Reasons for Listing The Directors believe that Admission will enhance the standing of the Company, and will facilitate the expansion of the Company, by the acquisition of other companies or intellectual property rights for the issue of new shares rather than cash. Commenting on the Company's application for admission to AIM, Gavin Simonds, Greenchip's Chairman said: "Greenchip's admission to AIM is an important step in the Company's development. Currently we are seeing rapid changes, including corporate consolidation, within the markets in which we have an interest. Greenchip's ability to participate in these exciting developments will, I believe, be enhanced by its listing on AIM." Enquiries: Greenchip InvestmentsPlc Gavin Simonds 020 7518 9180 Malcolm Burne 020 7518 9180 Andrew Page 020 7518 9180 Fiske Plc James Harrison 020 7448 4700 Bell Pottinger Financial Kate Power 020 7427 7200 Directors and Senior Management Gavin Simonds (45), non-executive chairman. Gavin Simonds was formerly joint-managing director of InterContinental Hotels Group. He has over 12 years investment banking experience as a former director of both Kleinwort Benson and UBS Phillips & Drew. He is a non-executive director of London Clubs International Plc. Gavin Simonds is a chartered accountant. Alan Bentley (54), non-executive director. By profession a non-practising commercial barrister, Mr Bentley has over the last 16 years specialised in the funding and strategic management of small businesses, often via tax-efficient structures. He is chairman and chief executive officer of Childcare Corporation Plc and he is also non-executive chairman of Ecomextra Plc, which is traded on OFEX. Ian Burne (58), director. Ian Burne has 38 years business experience in banking, engineering, company secretarial work, business finance, retailing and company administration. Since 1977, he has held directorships in several companies, both private and listed. For the last ten years, Ian has been involved in the development of new products leading to technology commercialisation. He has also been responsible for the Greenchip group's financial and administrative functions. Malcolm Burne (56), chief executive officer. Malcolm Burne commenced his career as an equity analyst, later moving into financial journalism. He has worked as a venture capitalist and has founded a number of public and private companies, including Golden Prospect Plc an AIM listed company where he is executive chairman. Andrew Page (42), corporate finance director, is a chartered accountant. He spent six years with Kleinwort Benson's corporate finance department, following which he became senior vice president, corporate finance, at InterContinental Hotels Group. Prior to joining Greenchip, he was group finance director at Hanover International PLC, a listed hospitality group. Ian Wallis (38), investment director. Ian Wallis has previously held a number of senior finance and business development roles, including corporate finance executive at Blenheim Group PLC and managing director of Jackie Stewart's family motor racing team. Most recently, he was vice president corporate finance and business development for ResidenSea Limited, the $355 million start-up and pioneer of resort living at sea. He is a chartered accountant. Senior Management Nathan Steinberg (46), Financial Controller. Nathan Steinberg is a chartered accountant and a partner in the London based accountancy practise of Munslow Messias. He qualified in 1978 and is also a director of Golden Prospect Plc and Viking Internet Plc, which are listed on AIM. He provides his accountancy services to the Company through his practise. And major shareholders are interesting - from article in the Guardian ages ago: Focus: Greenchip E-finance: special report Greenchip Tuesday February 15, 2000 Another day, and another technology investment firm signals its intention to come to market. The torrent of money pouring into the net sector shows little sign of abating. It seems everyone is involved in the new gold rush. Entrepreneurs, bankers, management consultants, teenagers, celebrities - they are all having a go. Trying to sort the wheat from the chaff is a thankless task. Yesterday's new arrival was Greenchip, an Ofex-quoted vehicle which said it is looking for an Aim listing. It claims its "mission" is to secure marketing , manufacturing and other licence rights in technologies owned and developed outside Europe and introduce them to the continent. The focus is on the internet and life sciences. Deal flow is maintained through a strategic alliance with Oceanic Management, a north American technology ventures company. The Greenchip model is a slightly different one from the traditional investment and incubator offerings and, after taking a glance at the shareholder list, appears a little more fruity than many others. Almost inevitably Luke Johnson, surely one of the most prolific investors in small internet investment companies, features prominently. Mr Johnson, on behalf of his Intrinsic Value listed investment trust and on his own account, owns around 10%. John Gunn, former director of British & Commonwealth, holds a further 9%. Arlington Group, another Ofex-listed investment group which counts Kerry Packer's family business, JellyWorks' David Rowland and Mr Johnson among its investors, holds a further 14%. Gavin Simonds, a former director of UBS and Kleinwort Benson, is to be chairman. Having floated British Steel and Abbey National his role will be to add investment banking expertise. Shareholders are bullish, management confident and the move away from the lightly regulated Ofex market likely to improve Greenchip's profile. But whether they can deliver value investments in such a volatile area is still unclear. Kevin prescott |
Posted at 01/11/2000 17:27 by topdog The bottom appears to have dropped out of this share and I'm not really sure why.Anyone shed any light on this and the chances it will bounce back? |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
